StockData
IN8bio, Inc. logo

IN8bio, Inc. (INAB) shareholders

INABNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 6/30
$0.82+0.00 (+0.49%)

Close on Nov 17, 2026Market cap $8.08MP/E –Yield –

Ownership

Institutional holdings as of Jun 30, 2026, from 13F filings

Held by institutions
38.4%
4M of 10M shares
Institutional holders
21
3 new, 1 sold out
Net institutional buying
0M
In Q2 2026
Insider trades, 12 months
0 buys · 0 sales
Open-market trades only

Shares held by institutions

Holders of more than 5%

Latest Schedule 13D (active) or 13G (passive) filed by each holder

HolderShares% of classFilingAs of
Bios Advisors Gp, LLC
Joint filing with Bios Capital Management, LP (9.99%), Aaron G.L. Fletcher (9.99%) and 4 more
9,120,0739.90%13D (active) amendmentMay 2, 2025
Lytton-Kambara Foundation
Joint filing with Lytton Laurence W (9.99%)
1,056,5139.99%13G (passive) amendmentJun 30, 2026
Stonepine Capital, L.P.
Joint filing with Stonepine Capital Management, LLC (9.90%), Stonepine GP, LLC (9.90%) and 1 more
1,007,9909.90%13G (passive)Dec 19, 2025
Lytton Laurence W
Joint filing with Lytton-Kambara Foundation (9.99%)
984,0319.99%13G (passive)Dec 22, 2025
Alyeska Investment Group, L.P.
Joint filing with Alyeska Fund GP, LLC (9.90%), Anand Parekh (9.90%)
966,3819.90%13G (passive)Dec 31, 2025
Franklin Advisers, Inc.
Joint filing with Franklin Resources, Inc. (9.40%)
914,5319.40%13G (passive)Dec 31, 2025
683 Capital Management, LLC
Joint filing with 683 Capital Partners, LP (7.86%), Ari Zweiman (7.86%)
770,4457.86%13G (passive)Dec 22, 2025

Top institutional holders

13F holdings as of Jun 30, 2026

HolderShares% of INABValueChange% of portfolio
Alyeska Investment Group, L.P.944,3199.58%$1.33M–0.00%
Franklin Resources Inc914,5319.28%$1.29M–0.00%
683 Capital Management, LLC724,6377.35%$1.02M–0.05%
Stonepine Capital Management, LLC695,2877.05%$980.36K+31,8750.55%
Vanguard Capital Management LLC88,8650.90%$126.54K–0.00%
BIOS Capital Management, LP80,9570.82%$114.15K−86,8480.27%
Geode Capital Management, LLC72,5500.74%$102.30K−13,6890.00%
Citadel Advisors LLC63,0550.64%$88.91KNew0.00%
Oppenheimer & Co Inc63,0420.64%$88.89K+39,0090.00%
Vanguard Fiduciary Trust Co43,5700.44%$62.04K–0.00%
Captrust Financial Advisors33,2950.34%$46.95K–0.00%
Texas Capital Bank Wealth Management Services Inc24,4060.25%$34.41K+6560.00%
Northern Trust Corp21,7340.22%$30.65K+1,2940.00%
Renaissance Technologies LLC12,1000.12%$17.06KNew0.00%
Tower Research Capital LLC (TRC)3,7380.04%$5.27K+2,4730.00%
Northwestern Mutual Wealth Management Co2,7850.03%$3.93K–0.00%
Jones Financial Companies Lllp7680.01%$1.04K–0.00%
BlackRock, Inc.840.00%$118–0.00%
Rockefeller Capital Management L.P.830.00%$117–0.00%
Barclays PLC280.00%$39New0.00%

Institutional buying and selling by quarter

Positions opened, added to, reduced and closed by 13F filers

QuarterHoldersShares held% of sharesNew / addedReduced / closedShares boughtShares sold
Q2 2026214M38.4%3 / 53 / 10M0M
Q1 2026194M38.1%3 / 46 / 51M0M
Q4 2025223M32.7%7 / 76 / 42M0M
Q3 2025191M9.9%8 / 43 / 10M0M
Q2 2025121M8.9%1 / 74 / 170M0M
Q1 2025281M7.3%6 / 67 / 40M0M
Q4 2024261M10.2%5 / 106 / 51M0M
Q3 2024260M2.6%6 / 66 / 50M0M
Q2 2024260M2.6%3 / 95 / 90M0M
Q1 2024320M2.9%6 / 87 / 40M0M
Q4 2023300M2.9%9 / 76 / 00M0M
Q3 2023210M0.8%3 / 83 / 40M0M

Top mutual fund and ETF holders

Latest monthly portfolio reports (Form N-PORT)

8 funds held INAB in Q2 2026, 18% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.

FundShares% of INABValue% of fundAs of
Franklin Biotechnology Discovery Fund332,0833.37%$345.37K0.03%Jul 31, 2026
Vanguard Extended Market Index Fund88,8650.90%$125.30K0.00%Jun 30, 2026
Fidelity Extended Market Index Fund63,6110.65%$118.95K0.00%May 31, 2026
Fidelity Series Total Market Index Fund8,3200.08%$15.56K0.00%May 31, 2026
Fidelity Total Market Index Fund2,0400.02%$3.81K0.00%May 31, 2026
Fidelity Nasdaq Composite Index Fund5670.01%$1.06K0.00%May 31, 2026
Blackstone Alternative Multi-Strategy Fund2000.00%$2820.00%Jun 30, 2026
Vanguard Total Stock Market Index Fund00.00%$00.00%Jun 30, 2026

Officers, directors and major owners

People who filed Forms 3, 4 or 5 in the last two years

NameRoleShares owned% of sharesLatest filing
William Tai-Wei HoCEO, Director124,8171.27%May 12, 2026
Kate RochlinPresident and COO9,0850.09%May 12, 2026
Patrick McCallCHIEF FINANCIAL OFFICER9,4820.10%May 12, 2026
Lawrence LambEVP and CSO101,3691.03%May 12, 2026
Emily FairbairnDirector0–May 29, 2026
Luba GreenwoodDirector7,8260.08%May 12, 2026
Peter C. BrandtDirector98,6901.00%May 12, 2026
Jeremy R. GraffDirector4,5490.05%May 12, 2026
Corinne EpperlyDirector81,9670.83%May 12, 2026
Alan S. RoemerDirector49,5140.50%Dec 23, 2025
Travis WhitfillDirector––Dec 23, 2024
BIOS Advisors GP, LLC10% owner540,2875.48%May 7, 2025
BIOS Fund II QP, LP10% owner8,600,00187.24%May 7, 2025
BIOS Fund II NT, LP10% owner561,9895.70%May 7, 2025
BP Directors, LP10% owner8,600,00187.24%May 7, 2025
Cavu Advisors, LLC10% owner559,0765.67%May 7, 2025
BIOS Incysus Co-Invest I, LP10% owner––May 7, 2025
BIOS Equity Partners III, LP10% owner––May 7, 2025
BIOS Fund III, LP10% owner––May 7, 2025
BIOS Fund III QP, LP10% owner570,7245.79%May 7, 2025
BIOS Fund III NT, LP10% owner8,600,00187.24%May 7, 2025
Cavu Management, LP10% owner3,612,56936.64%May 7, 2025
Leslie W. Kreis10% owner570,7245.79%May 7, 2025
Aaron G.L. Fletcher10% owner––May 7, 2025
Bios Equity COF, LP10% owner––May 7, 2025
Bios Clinical Opportunity Fund, LP10% owner––May 7, 2025
Bios Equity Partners II, LP10% owner8,600,00187.24%May 7, 2025
BIOS Fund II, LP10% owner8,600,00187.24%May 7, 2025
BIOS Capital Management, LP10% owner8,600,00187.24%May 7, 2025
Bios Equity Partners, LP10% owner––May 7, 2025

Insider trades

Common stock transactions reported on Form 4, newest first

InsiderDateTransactionSharesPriceValueShares after
Emily Fairbairn
Director
May 27, 2026Gift−724,637––0
Peter C. Brandt
Director
Dec 22, 2025Award+72,464$1.38$100.00K95,181
Patrick McCall
CHIEF FINANCIAL OFFICER
Dec 22, 2025Award+7,247$1.38$10.00K9,482
William Tai-Wei Ho
PRESIDENT AND CEO, Director, 10% owner
Dec 22, 2025Award+36,232$1.38$50.00K121,168
Emily Fairbairn
Director
Dec 22, 2025Award+724,637$1.38$1,000.00K724,637
Kate Rochlin
Chief Operating Officer
Dec 22, 2025Award+7,247$1.38$10.00K9,085
Alan S. Roemer
Director
Dec 22, 2025Award+36,232$1.38$50.00K49,514
Peter C. Brandt
Director
Apr 30, 2025Option exercise+81,967$0.18$14.75K681,538
Peter C. Brandt
Director
Apr 30, 2025Option exercise+81,967$0.18$14.75K599,571
Patrick McCall
CHIEF FINANCIAL OFFICER
Apr 30, 2025Option exercise+15,000$0.18$2.70K67,071
Kate Rochlin
Chief Operating Officer
Apr 30, 2025Option exercise+12,295$0.18$2.21K55,169
Alan S. Roemer
Director
Apr 30, 2025Option exercise+102,459$0.18$18.44K387,489
Alan S. Roemer
Director
Apr 30, 2025Option exercise+11,000$0.18$1.98K398,489
Patrick McCall
CHIEF FINANCIAL OFFICER
Oct 4, 2024Award+25,316––52,071
Alan S. Roemer
Director
Oct 4, 2024Award+126,582––285,030
Kate Rochlin
Chief Operating Officer
Oct 4, 2024Award+25,316––42,874
Peter C. Brandt
Director
Oct 4, 2024Award+253,164––517,604
William Tai-Wei Ho
PRESIDENT AND CEO, Director, 10% owner
Oct 4, 2024Award+126,582––2,548,094
William Tai-Wei Ho
President and CEO, Director, 10% owner
Dec 13, 2023Award+81,967––2,421,512
Lawrence Lamb
EVP and CSO
Dec 13, 2023Award+1,639––101,369
Trishna Goswami
Chief Medical Officer
Dec 13, 2023Award+4,098––6,729
Peter C. Brandt
Director
Dec 13, 2023Award+81,967––264,440
Kate Rochlin
Chief Operating Officer
Dec 13, 2023Award+12,295––17,558
Alan S. Roemer
Director
Dec 13, 2023Award+102,459––158,448
Corinne Epperly
Director
Dec 13, 2023Award+81,967––81,967
Jeremy R. Graff
Director
Dec 13, 2023Award+2,049––4,549
Patrick McCall
Chief Financial Officer
Dec 13, 2023Award+20,492––26,755
Jeremy R. Graff
Director
Sep 13, 2023Buy+2,500$0.95$2.38K2,500
Patrick McCall
Chief Financial Officer
Aug 25, 2023Buy+1,000$1.03$1.03K6,263
William Tai-Wei Ho
President and CEO, Director, 10% owner
Aug 24, 2023Buy+23,800$1.05$24.99K2,339,545
Emily Fairbairn
Director
Jul 28, 2023Other−4,111,958––0
Leslie W. Kreis
Director, 10% owner
Dec 12, 2022Buy+8,735$2.48$21.66K570,724
Leslie W. Kreis
Director, 10% owner
Dec 12, 2022Buy+9,214$2.48$22.85K601,980
Leslie W. Kreis
Director, 10% owner
Dec 12, 2022Buy+57,052$2.48$141.49K3,727,597
BIOS Fund III QP, LP
Director, 10% owner
Dec 12, 2022Buy+8,735$2.48$21.66K570,724
BIOS Fund III QP, LP
Director, 10% owner
Dec 12, 2022Buy+9,214$2.48$22.85K601,980
BIOS Fund III QP, LP
Director, 10% owner
Dec 12, 2022Buy+57,052$2.48$141.49K3,727,597
BIOS Fund II NT, LP
Director, 10% owner
Sep 28, 2022Buy+2,913$2.02$5.88K561,989
BIOS Fund II NT, LP
Director, 10% owner
Sep 28, 2022Buy+19,017$2.02$38.41K3,670,545
BIOS Fund II NT, LP
Director, 10% owner
Sep 28, 2022Buy+3,070$2.02$6.20K592,766
Bios Equity Partners II, LP
Director, 10% owner
Sep 28, 2022Buy+2,913$2.02$5.88K561,989
Bios Equity Partners II, LP
Director, 10% owner
Sep 28, 2022Buy+19,017$2.02$38.41K3,670,545
Bios Equity Partners II, LP
Director, 10% owner
Sep 28, 2022Buy+3,070$2.02$6.20K592,766
Cavu Advisors, LLC
Director, 10% owner
Aug 29, 2022Buy+4,660$2.02$9.41K559,076
Cavu Advisors, LLC
Director, 10% owner
Aug 29, 2022Buy+4,912$2.02$9.92K589,696
Cavu Advisors, LLC
Director, 10% owner
Aug 29, 2022Buy+30,428$2.02$61.46K3,651,528
BIOS Fund II QP, LP
Director, 10% owner
Aug 29, 2022Buy+4,660$2.02$9.41K559,076
BIOS Fund II QP, LP
Director, 10% owner
Aug 29, 2022Buy+4,912$2.02$9.92K589,696
BIOS Fund II QP, LP
Director, 10% owner
Aug 29, 2022Buy+30,428$2.02$61.46K3,651,528
Cavu Advisors, LLC
Director, 10% owner
Aug 26, 2022Buy+1,377$2.01$2.77K584,784
Cavu Advisors, LLC
Director, 10% owner
Aug 26, 2022Buy+8,531$2.01$17.15K3,621,100
Cavu Advisors, LLC
Director, 10% owner
Aug 26, 2022Buy+1,306$2.01$2.63K554,416
BIOS Fund II QP, LP
Director, 10% owner
Aug 26, 2022Buy+1,377$2.01$2.77K584,784
BIOS Fund II QP, LP
Director, 10% owner
Aug 26, 2022Buy+8,531$2.01$17.15K3,621,100
BIOS Fund II QP, LP
Director, 10% owner
Aug 26, 2022Buy+1,306$2.01$2.63K554,416
Cavu Management, LP
Director, 10% owner
Aug 17, 2022Buy+38,035$1.93$73.41K3,612,569
Cavu Management, LP
Director, 10% owner
Aug 17, 2022Buy+5,823$1.93$11.24K553,110
Cavu Management, LP
Director, 10% owner
Aug 17, 2022Buy+6,142$1.93$11.85K583,407
BIOS Fund II NT, LP
Director, 10% owner
Aug 17, 2022Buy+5,823$1.93$11.24K553,110
BIOS Fund II NT, LP
Director, 10% owner
Aug 17, 2022Buy+38,035$1.93$73.41K3,612,569

Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.

Short interest

Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)

Short % of shares outstanding
0.16%
0M shares short
Days to cover
1.0
At 0M shares a day
Change since last report
-52.0%
From 0M shares
Short volume, 20 days
30.6%
Of volume reported to FINRA

Shares sold short, last 12 months

Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of IN8bio's stock actually held short. No settlement fails above the SEC's reporting threshold in the last 90 days.

See a number that looks wrong?